GENinCode has reported its results for the 12 months to December 2023, generating revenues of £2.2m, up 51% YoY and in line with our forecast. We believe the company has made strong operational progress through FY23 and into FY24, with tests launched in the US via the Early Access Program, progress achieved with LIPID inCode in the UK through the NHS and expansion in the European market via a collaboration with MVZ Uniklinikum. Significantly, the company closed the year with a strong cash balanc ....
